1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update for the Infectious
Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–e120.
2. Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev.2012 Oct; 2012(10): CD003265.
3. de Zeeuw J, Gillissen AG: Nitrofurantoin-induced pulmonary injury. UpToDate. Post TW (ed): UpToDate, Waltham, MA; 2018.
4. Gilbert DN. Urinary tract infections in patients with chronic renal insufficiency. Clin J Am Soc Nephrol 2006; 1.
5. Vervoort J, Xavier BB, Stewardson A et al. Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota. J Antimicrob Chemother 2015; 70.
6. Cunha BA, Shoch PE, Hage JR. Nitrofurantoin: preferred empiric therapy for community-acquired lower urinary tract infections. Mayo Clin Proc. 2011;86:1243–1248.
7. Munoz-Davila, M. J. (2014). Role of old antibiotics in the era of antibiotic resistance: highlighted nitrofurantoin for the treatment of lower urinary tract infections. Antibiotics (Basel) 3 (1),
39–48.
8. Horton JM. Urinary Tract Agents: Nitrofurantoin, fosfomycin and Methenamine. In: Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases, 9th edition, Chur-
chill Livingstone, New York ,2020, p 461-465.
9. Gautam, G., Gogoi, S., Saxena, S., Kaur, R., and Dhakad, M. S. (2021). Nitrofurantoin susceptibility pattern in gram-negative urinary isolates: in need of increased vigilance. J. Lab. Physicians
13 (3), 252–256.
10. Karabay, O, Eroğlu, M, Semerciöz, A, Koçoğlu E. Toplum kaynaklı erişkin üriner sistem infeksiyonlarında izole edilen enterobaktericea türlerinin bazı antibiyotiklere duyarlılıkları: geriye
dönük çalışma. Türk Üroloji Dergisi/Turkish Journal of Urology, 2007; 33(1), 100-103.
11. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revised. Med Clin North Am 2006;90:1089–1107.
12. Aytaç Ö, Mumcuoğlu İ, Çetin F, Aksoy A, Aksu N. Erişkin hastalarda toplum kaynaklı üriner sistem infeksiyonlarından izole edilen Escherichia coli suşlarının antibiyotik duyarlılıklarının
yıllara göre değişimi (2010-2014). Turk Hij Den Biyol Derg, 2015; 72(4): 273-280.
13. Alpay Y, Yavuz MT, Aslan T, Büyükzengin B. Genişlemiş spektrumlu beta-laktamaz pozitif escherıchıa colı ile oluşan komplike olmayan üriner sistem infeksiyonlarının tedavisinde oral anti-
biyotikler karbapenemlere alternatif olabilir mi? ANKEM Derg 2017;31(3):85-91.
14. Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, Darbandi T, Ghanavati R, Darbandi A. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a
narrative review. Front Cell Infect Microbiol 2023 Jul 27:13:1148603
15. McKinnell JA, Stollenwerk NS, Jung CW, et al. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and
cost analysis. Mayo Clin Proc. 2011;86:480–488.
16. Long, B., and Koyfman, A. (2018). The emergency department diagnosis and management of urinary tract infection. Emerg. Med. Clin. North Am. 36 (4), 685–710.
17. Kostakioti, M., Hultgren, S. J., and Hadjifrangiskou, M. (2012). Molecular blueprint of uropathogenic Escherichia coli virulence provides clues toward the development of anti-virulence the-
rapeutics. Virulence 3 (7), 592–594.
18. Schlager TA, Anderson SM, Trudell JM. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Pediatr.
1998;132:704–708.
19. Raz R, Colodner R, Rohanna Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in
postmenopausal women. Clin Infect Dis 2003;36:1362–1368.
20. Tatley M: Pulmonary reactions with nitrofurantoin . Prescriber Update. 2002, 23:24-5.
21. Suliman AM, Alamin MA, Haq IU. Nitrofurantoin-Induced Lung Injury: A Reminder of an Overlooked Threat. Cureus. 2023 Sep 5;15(9):e44730.
22. Kabbara WK, Kordahi MC. Nitrofurantoin-induced pulmonary toxicity: A case report and review of the literatüre. J Infect Public Health 2015, 8:309-13.
23. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother
2015 Sep;70(9):2456-64.
24. Sherigar JM, Fazio R, Zuang M, Arsura E. Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease. Clin Pract. 2012
Oct 12; 2(4): e83.
25. Santos JM, Batech M, Pelter MA, et al. Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system.
J Am Geriatr Soc 2016;64:798–805.
26. Shah R, Wade G. Reappraisal of the risk/benefit of nitrofurantoin Adverse Drug React Acute Poisoning Rev 1989;8:183–201.
27. ACOG Committee Opinion No. 404. Sulfonamides, nitrofurantoin and risk of birth defects. Obstet Gynecol 2011;117:1484–1485.
28. Zao J, Koren G, Bozzo P. Using nitrofurantoin while breastfeeding a newborn. Can Fam Physician. 2014;60: 539–540.
29. Raz R. Fosfomycin: an old–new antibiotic. Clin Microbiol Infect. 2012;18:4–7.
30. Park KS, Kim DR, Baek JY, Shin A, Kim KR, Park H, Son S, Cho H, Kim YJ. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive Escherichia coli and Klebsiella pneumoniae
Isolated From Urine of Pediatric Patients. J Korean Med Sci. 2023 Dec 11;38(48):e361.
31. Liu HY, Lin HC, Lin YC, et al. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofu-
rantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect. 2011;44:364–368.
32. Butcu M, Akcay SS, Inan AS, et al. In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics. J Infect Chemother. 2011;17:575–578.
33. Bakır M. Nitrofurantoin, Metenamin , Fosfomisin. In: Willke Topçu A, Söyletir G, Doğanay M,eds. İnfeksiyon hastalıkları ve Mikrobiyolojisi 4. Baskı. İstanbul;2017.
34. UpToDate: Fosfomycin Drug Information. 2013. http://www.uptodate.com/contents/fosfomycin-drug-information.
35. Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase— producing Escherichia coli—related lower urinary tract infections. Int J Anti-
microb Agents. 2007;29:62–65.
36. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase–producing Escherichia coli. Arch Intern Med. 2008;168:1897–1902.
37. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J
Antimicrob Chemother. 2010;65:2459–2463.
38. Sen V, Aydogdu O, Bozkurt I, et al. The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and
controlled clinical study. Can Urol Assoc J. 2015;9:E863–E867.
39. UpToDate: methenamine drug information. http:// www.uptodate.com/contents/methenamine-drug-information.
40. Harding C, Chadwick T, Homer T, Lecouturier J, Mossop H, Carnell S, King W, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K,
Walton K, Hussain Z, Lazarowicz H, Ali A. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority
RCT. Health Technol Assess. 2022 May;26(23):1-172.